Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

BACKGROUND: Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin level has been reported to be associated with ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhihong, Fan, Shengjun, Zheng, Jing, Huang, Wei, Gasparetto, Cristina, Chao, Nelson J., Hu, Jianda, Kang, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828316/
https://www.ncbi.nlm.nih.gov/pubmed/29482577
http://dx.doi.org/10.1186/s13045-018-0575-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828316/
https://www.ncbi.nlm.nih.gov/pubmed/29482577
http://dx.doi.org/10.1186/s13045-018-0575-7

Ejemplares similares